Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause?. Experimental vs. clinical data

Journal of Steroid Biochemistry and Molecular Biology

Volumn 109, Issue 1-2, 2008, Pages 11-15

  Seeger, Harald ^a   Mueck, Alfred O ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Breast cancer risk; Clinical data; Experimental data; Progestins

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; PROGESTERONE;

APOPTOSIS; BREAST CANCER; BREAST EPITHELIUM; CANCER RISK; CELL PROLIFERATION; ESTROGEN THERAPY; HORMONAL THERAPY; HUMAN; POSTMENOPAUSE; REVIEW;

AGED; BREAST; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; EPIDEMIOLOGIC STUDIES; EPITHELIAL CELLS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PROGESTERONE CONGENERS; RISK FACTORS;

EID: 40849092530     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.12.002     Document Type: Review

References (32)

1. Writing Group for the Women's Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women, JAMA 288 (2002) pp. 321-333.
2. The Women's Health Initiative Steering Committee, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy, JAMA 291 (2004) pp. 1701-1712.
3. van der Burg B., Kalkhoven E., Isbrücker L., and de Laat S.W. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J. Steroid Biochem. Mol. Biol. 42 (1992) 457-465
4. Catherino W.H., Jeng M.H., and Jordan V.C. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br. J. Cancer 67 (1993) 945-952
5. Schoonen W.G.E.J., Joosten J.W.H., and Kloosterboer H.J. Effects of two classes of progestins, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: 1. MCF-7 cell lines. J. Steroid Biochem. Mol. Biol. 55 (1995) 423-437
6. Cappelletti V., Miodini P., Fioravanti L., and DiFronzo G. Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines. Anticancer Res. 15 (1995) 2551-2556
7. Krämer E.A., Seeger H., Krämer B., Wallwiener D., and Mueck A.O. The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. Eur. J. Obstet. Gynecol. Reprod. 27 (2006) 139-141
8. Soule H.D., Maloney T.M., Wolman S.R., Peterson W.D., Brenz R., McGrath C.M., Russo J., Pauley R.J., Jones R.F., and Brooks S.C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50 (1990) 6075-6086
9. Dickson R.B., and Lippman M.E. Growth factors in breast cancer. Endocr. Rev. 16 (1995) 559-589
10. Gazdar A.F., Kurvari V., Virmani A., Gollahon L., Sakaguchi M., Westerfield M., Kodagoda D., Stasny V., Cunningham H.T., Wistuba I.I., Tomlinson G., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., and Shay J.W. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78 (1998) 766-774
11. Black W.C., and Welch H.G. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N. Engl. J. Med. 328 (1993) 1237-1243
12. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., and Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283 (2000) 485-491
13. Ross R.K., Paganini-Hill A., Wan P.C., and Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92 (2000) 328-332
14. Chen W.Y., Colditz G.A., Rosner B., Hankinson S.E., Hunter D.J., Manson J.E., Stampfer M.J., Willett W.C., and Speizer F.E. Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer. Ann. Intern. Med. 137 (2002) 798-804
15. Newcomb P.A., Titus-Ernsthoff L., Egan K.M., Trentham-Dietz A., Baron J.A., Storer B.E., Willett W.C., and Stampfer M.J. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 593-600
16. Weiss L.K., Burkman R.T., Cushing-Haugen K.L., Voigt L.F., Simon M.S., Daling J.R., Norman S.A., Bernstein L., Ursin G., Marchbanks P.A., and Berlin J.A. Hormone replacement therapy regimens and breast cancer risk. Obstet. Gynecol. 100 (2002) 1148-1158
17. Porch J.V., Lee I.-M., Cook N.R., Rexrode K.M., and Buring J.E. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (Unites States). Cancer Causes Control 13 (2002) 847-854
18. Hulley S., Furberg C., Barrett-Connor E., Cauley J., Grady D., Haskell W., Knoop R., Lowery M., Scatterfield S., Schrott H., Vittinghoff E., and Hunninghake D. Nonvascular disease outcomes during 6.8 years of hormone therapy (Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 288 (2002) 58-66
19. Li C.I., Malone K.E., and Porter P.L. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289 (2003) 3254-3263
20. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., Rodabough R.J., Gilligan M.A., Cyr M.G., Thomson C.A., Khandekar J., and Petrovitch H. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women (The Women's Health Initiative Randomized Trial). JAMA 289 (2003) 3243-3253
21. Lee S., Kolonel L., Wilkens L., Wan P., Henderson B., and Pike M.C. Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int. J. Cancer 118 (2006) 1285-1291
22. Persson I., Thurfjell E., Bergström R., and Holmberg L. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int. J. Cancer 72 (1997) 758-761
23. Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.-O., and Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int. J. Cancer 81 (1999) 339-344
24. Million Women Study Collaborators, Breast cancer and hormone-replacement therapy in the Million Women Study, Lancet 362 (2003) pp. 419-427.
25. De Lignieres B., De Vathaire F., Fournier S., Urbinelli R., Allaert F., Le M.G., and Kuttenn F. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 5 (2002) 332-340
26. Olsson H.L., Ingvar C., and Bladström A. Hormone replacement therapy containing progestins and given continuously increases breast cancer carcinoma risk in Sweden. Cancer 97 (2003) 1387-1392
27. Jernstrom H., Bendahl P.-O., Lidfeldt J., Nerbrand C., Agardh C.-D., and Samsioe G. A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden). Cancer Causes Control 13 (2003) 673-680
28. Stahlberg C., Pedersen A.T., Lynge E., Andersen Z.J., Keiding N., Hundrup Y.A., Oberl E.B., and Ottesen B. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int. J. Cancer 109 (2004) 721-727
29. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. 107 (2008) 103-111
30. Farmer R. The million women study - is it believable?. Climacteric 8 (2005) 210-213
31. Wiebe J.P., Lewis M.J., Cialacu V., Pawlak K.J., and Zhang G. The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics. J. Steroid Biochem. Mol. Biol. 93 (2005) 201-208
32. L. Opatmy, S. Dell'Aniello, S. Assouline, S. Suissa, Hormone replacement therapy and variations in the risk of breast cancer, American Association to Cancer Research (AACR), April 1-5, 2006, Washington (D.C.); abstract no. LB 331.